I'm not talking about the new investors who approached...

First 19 Last

Share
Profile

Follow
IndexInvestor

9,048 Posts.

1472

29/10/24

03:54

Post #: 76343748
Share

Originally posted by 88888acct: ↑

Hi IndexInvestor,

I just logged on with the hope to read constructive discussion about the company's assets and the exciting months ahead, but I'm disappointed to see it continues to be spammed by you.

You appear to keep disregarding other people's opinions and repeating your own points over and over again. It's bordering on disrespectful to the other shareholders who want to focus on the company's bright future.

Please vote and let your grudge die on the vine, or consider selling your shares, for everyones sake.

If you choose to hold, instead of playing the victim, how about taking some personal accountability. The fact is we all inc you had plenty of chances to participate in the pro-rata entitlement issue at 6 cents with 1:1 options. There was even a top-up available, and full top-up applications were granted. After the acquisition, you had more than enough time to do your due diligence on Galidesivir based on all the published information and buy it when it was under 7 cents. The listed options were also tradable.

Please show some respect to the other shareholders who disagree with you and are grateful for the caliber of the new investors. Rather than attempting to drive them away with your constant negative posts.

The new investors have substantially reduced the company's risk in the eyes of many because of the technical due diligence they must have done prior to approaching the company. It was so refreshing not to have the usual post-raise indigestion. I, for one, am thankful that our new board member chose to put in hurt money/skin in the game that he paid for, instead of just getting free stock through ESOP like the majority of other BoDs and management personnel do.

My sense is the majority of shareholders saw the raise as well managed (this hypothesis will be confirmed by way of the AGM poll), and it also reduces future dilution because the company can now raise capital at a premium to where it would otherwise be trading, instead of a significant discount.

At any rate, you've made your point, and you've made it multiple times of several weeks. Can we please move on and start talking about the bright future the company has now that it's funded for both ISLA-101 and Galidesivir?

Expand

I'm not talking about the new investors who approached ILA.

I'm talking about the Director who grabbed some of their free 7c options for himself.

If you can't see the difference, please ask.

ILA Price at posting: 12.5¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

'Not possible' to port renewable gas: ACCC takes AGN to court

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Thursday's HotCopper trends: Paradigm's drug IP buy, MTM placement | June 26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NEU

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

First 19 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 15.5¢		Change 0.020(14.8%)		Mkt cap ! $34.23M

Open	High	Low	Value	Volume
13.5¢	15.5¢	13.0¢	$45.41K	312.4K

Buyers (Bids)

No.	Vol.	Price($)
2	30884	15.0¢

Sellers (Offers)

Price($)	Vol.	No.
15.5¢	42405	4

View Market Depth

No.	Vol.	Price($)
2	30884	0.150
3	75884	0.145
1	250000	0.140
6	375192	0.130
4	132001	0.125

Price($)	Vol.	No.
0.155	42405	4
0.160	23844	3
0.165	66653	3
0.170	103546	2
0.180	130303	2

Last trade - 15.07pm 26/06/2025 (20 minute delay)

ILA (ASX) Chart

I'm not talking about the new investors who approached...

'Not possible' to port renewable gas: ACCC takes AGN to court

Australia’s gas crisis is here – and dying coal plants aren’t helping

Thursday's HotCopper trends: Paradigm's drug IP buy, MTM placement | June 26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I&apos;m not talking about the new investors who approached...

Top Stories

'Not possible' to port renewable gas: ACCC takes AGN to court

Australia’s gas crisis is here – and dying coal plants aren’t helping

Thursday's HotCopper trends: Paradigm's drug IP buy, MTM placement | June 26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I'm not talking about the new investors who approached...